Abstract-Vascular injury is an early manifestation in hypertension and a cause of end-organ damage. MicroRNAs play an important role in cardiovascular disease, but their implication in vascular injury in hypertension remains unclear. This study revealed using an unbiased approach, microRNA and mRNA sequencing with molecular interaction analysis, a microRNA-transcription factor coregulatory network involved in vascular injury in mice made hypertensive by 14-day Ang II (angiotensin II) infusion. A candidate gene approach identified upregulated miR-431-5p encoded in the conserved 12qF1 (14q32 in humans) microRNA cluster, whose expression correlated with blood pressure, and which has been shown to be upregulated in human atherosclerosis, as a potential key regulator in Ang II-induced vascular injury. Gain-and loss-of-function in human vascular smooth muscle cells demonstrated that miR-431-5p regulates in part gene expression by targeting ETS homologous factor. In vivo miR-431-5p knockdown delayed Ang II-induced blood pressure elevation and reduced vascular injury in mice, which demonstrated its potential as a target for treatment of hypertension and vascular injury.
A ng II (Angiotensin II) is a major component of the reninangiotensin-aldosterone system that participates in the development of hypertension. 1 It causes blood pressure (BP) elevation through vasoconstriction and its renal actions and induces small artery injury characterized by endothelial dysfunction and vascular remodeling, stiffening, oxidative stress, and inflammation. 2 Small artery remodeling may be the earliest manifestation of target-organ damage in essential hypertension. 3 Understanding the molecular mechanisms underlying small artery injury may allow identification of novel therapeutic targets.
MicroRNAs (miRNAs) are gene regulatory small noncoding RNAs of about 22 nucleotides that play a posttranscriptional role in developmental, physiological, and pathophysiological processes. 4, 5 miRNAs regulate gene expression by binding to the 3′ untranslated region (UTR) of their target mRNAs to induce mRNA translation repression and degradation. They can target multiple mRNAs, 6 including TF (transcription factor)-encoded mRNAs, suggesting a key regulator potential on gene expression and potential as therapeutic targets.
A miR-143/145 cluster knockout and an inducible smooth muscle cell (SMC)-specific Dicer knockout have demonstrated that miRNAs are important regulators of the contractile phenotype of vascular SMCs (VSMCs).
7-9 miRNA dysregulation could contribute to the development of vascular injury in hypertension. Despite studies of vascular miRNA dysregulation in hypertension using microarrays, 10, 11 it is unclear whether known miRNAs play roles in vascular injury in hypertension. Using next-generation sequencing, Londin et al 12 discovered that human miRNAs are more numerous than reported in public repositories.
We hypothesized that miRNAs drive gene expression changes leading to vascular injury and could be novel targets for treatment of hypertension. To test this hypothesis, we used a systems biology approach combining miRNA and mRNA profiling by next-generation sequencing and miRNA-mRNA/ TF-gene interaction analysis to reveal miRNA-TF coregulatory networks associated with Ang II-induced mesenteric artery (MA) injury. A candidate gene approach was then used to identify a potential miRNA regulator and interesting coregulatory targets such as TFs in Ang II-induced vascular injury. The interactions between different elements of the selected key miRNA-TF coregulatory network were validated by gain-or loss-of-function experiments in human vascular cells. Finally, we tested whether in vivo knockdown of the selected miRNA protects against Ang II-induced BP elevation and vascular damage.
Methods
Expanded Methods are provided in the online-only Data Supplement. The data and analytic methods but not the study materials, because of the limited amount of tissues and RNA available, will be/have been made available to other researchers for the purpose of reproducing the results or replicating the procedure. The sequencing data have been deposited in the Gene Expression Omnibus database, www.ncbi.nlm. nih.gov/geo (accession no. GSE101711). The authors declare that all supporting data are available within the article and in the online-only Data Supplement.
Experimental Design
The study was approved by the Animal Care Committee of the Lady Davis Institute for Medical Research and McGill University and followed recommendations of the Canadian Council of Animal Care.
A group of 10-to 12-week-old male C57BL/6NHsd mice (Harlan Laboratories, Indianapolis, IN) (n=10-13) infused subcutaneously or not with Ang II (1000 ng/kg per minute) for 7 or 14 days were used to determine changes of miRNA and mRNA expression in MAs by RNA sequencing ( Figure 1A ). BP was determined by telemetry in a subset of the above mice (n=5 for control and n=6 for Ang II-infused). The second group of 10-to 12-week-old male C57BL/6NHsd mice (n=7) infused or not with Ang II for 7 or 14 days were used to assess MA function and mechanical properties by pressurized myography ( Figure 1A) .
Small (n=8) and total RNAs (n=6) were sequenced using the HiSeq 2500 sequencing system (Illumina, San Diego, CA) at the CHU Sainte-Justine Integrated Centre for Pediatric Clinical Genomics. A bioinformatics pipeline ( Figure 1A ) was used to study expression profiles of known and novel miRNAs and of mRNAs, predict miRNA targets from the inversely related differentially expressed (DE) mRNAs, identify TFs among DE mRNAs and predict their targets, perform functional enrichment analysis and construct molecular networks integrating the above interactions and the miRNA and mRNA expression profiles.
Thereafter, a candidate gene approach was used to identify miR-431-5p as potential miRNA regulator and the TF ETS homologous factor (Ehf) as an important coregulatory target in Ang II-induced vascular injury ( Figure 1B) .
Mouse MA SMCs and endothelial cells and fibroblasts isolated from 10-to 12-week-old male C57BL/6NHsd mice (n=12), and human aortic SMCs (HASMCs), endothelial cells, and fibroblasts obtained from ScienCell Research Laboratories (Carlsbad, CA) were used to determine vascular cell types expressing the selected key miRNA regulator miR-431-5p by reverse transcription-quantitative polymerase chain reaction (RT-qPCR; Figure 1C ). Oligonucleotide primers for mouse and human mRNA qPCR are listed in Table S1 in the online-only Data Supplement.
To determine whether human miR-431-5p targets EHF, the expression of EHF was measured by RT-qPCR in HASMCs transfected with miR-431-5p mimics or inhibitors ( Figure 1C) . A luciferase miRNA target expression vector assay (Promega, Madison, WI) was used to confirm whether miR-431-5p targets EHF in a canonical miRNA-targeting machinery in HASMCs transfected with miR-431-5p mimics or inhibitors. The oligonucleotides containing the EHF 3′ UTR with the wild-type or mutated miR-431-5p target region used to generate the luciferase constructs are presented in Table S2 . To test whether EHF targets α-1-type I collagen (COL1A1) and miR-382-5p, the expression of COL1A1 and miR-382-5p was determined by RT-qPCR in HASMCs transfected with EHF small interfering RNA.
To determine whether miR-431-5p knockdown protects against Ang II-induced BP elevation and vascular damage, another group of 10-to 12-week-old male C57BL/6NHsd mice (n=7) was infused with Ang II (1000 ng/kg per minute) for 14 days and injected intravenously via the tail vein with 20 mg/kg of LNA miR-431-5p inhibitor or a negative control (scrambled) LNA miRNA inhibitor (Exiqon, Vedbaek, Denmark) on day 1 and 7 of the treatment period ( Figure 1D ). BP was determined as above in a subset of these mice (n=6). At the end of the study, miRNA and mRNA expression was measured in MAs by RT-qPCR. MA function and mechanical properties were determined by pressurized myography in a separate group of 10-to 12-week-old male C57BL/6NHsd mice (n=7) treated as above.
Data Analysis
Acquisition of data was done by experimenters blinded to group/ treatment assignments. Results are presented as means±SEM.
Comparisons in BP and concentration-response curve data were performed using 2-way ANOVA for repeated measures. Other comparisons between >2 groups were done using 2-way ANOVA as indicated. All ANOVA tests were followed by a Bonferroni post hoc test. In absence of normal distribution, a Kruskal-Wallis 1-way ANOVA followed by a Dunn multiple comparison test was used to compare >2 groups. Comparisons between 2 groups were done using unpaired or paired t test as indicated. Correlation between DE miRNA or DE mRNA and systolic or diastolic BP was obtained using a Pearson correlation conducted in R. ANOVA and t tests were performed in SigmaPlot version 13 (Systat Software, San Jose, CA). P<0.05 was considered statistically significant. Differential expression analysis was performed using an ANOVA-like test in EdgeR based on generalized linear models. Differential expression was defined with a threshold of 1.5-fold change and false discovery rate <0.05.
Results
Ang II-Induced a miRNA-TF Coregulatory Network Associated With Vascular Injury miRNAs and mRNAs were profiled using next-generation sequencing in MAs at 2 stages of vascular injury in Ang II-induced hypertension model ( Figure 1A ). Ang II infusion caused BP elevation throughout the 14-day treatment period compared with the sham group ( Figure S1A ). Seven-day Ang II mice presented a developing stage of vascular injury whereas 14-day Ang II mice exhibited a developed stage of vascular injury (Figure S1B through S1E). Furthermore, kidney weight loss occurred in 7-and 14-day Ang II mice and cardiac hypertrophy in the latter (Table S3) .
Total RNA isolated from MAs (Table S4) with RNA integrity numbers >8.0 was selected for small (n=8) and total RNA sequencing (n=6). An average of 18.1±0.4 million single-end reads was obtained from small RNA sequences, 73.8±0.8% of which mapped to a single locus and 13.9±0.4% to multiple loci. Differential expression analysis identified one downregulated miRNA (miR-145a-3p) in the 7-day Ang II group, whereas 23 upregulated and 12 downregulated miRNAs were detected in the 14-day Ang II group (Table S5) . miR-145a-3p expression was unaffected in the 14-day Ang II group. Four of the 12 downregulated miRNAs are putative novel miRNAs not annotated in miRBase (http://www.mirbase.org, accessed on November 4, 2017, date last accessed). Hierarchical clustering analysis of DE miRNAs clustered the 14-day Ang II samples from the others (Figure 2A ).
An average of 35.6±0.7 million paired-end reads was obtained from total RNA sequences, 72.4±1.1% of which mapped to a single locus and 16.5±0.6% to multiple loci. One sample in the 14-day Ang II group was excluded because of low mapping % (19.4% to a single locus and 2.7% to multiple loci). Differential expression analysis identified 32 upregulated mRNAs and 11 downregulated mRNAs uniquely associated with the 7-day Ang II group, 440 upregulated mRNAs and 250 downregulated mRNAs uniquely associated with the 14-day Ang II group, whereas 110 upregulated mRNAs and 6 downregulated mRNAs overlapped in both groups (Tables S6 and S7 ). Hierarchical clustering analysis of the DE mRNAs clustered the 7-and 14-day Ang II samples in 2 distinct groups, whereas the 7-and 14-day sham samples clustered together ( Figure 2B ). The 7-day DE mRNAs were enriched in genes involved in ECM (extracellular matrix) and cell proliferation (Table S8) , whereas the 14-day DE mRNAs were enriched in many more genes involved in ECM and developmental processes, and other genes involved in cell motility, growth factor signaling, inflammation, cell proliferation, protein transport, peptidase activity, and apoptosis (Table S9) . Similar findings were obtained with the Kyoto Encyclopedia of Genes and Genomes and REACTOME pathway knowledgebase enrichment analysis (Table S10 ). mRNA targets of DE miRNAs were predicted with TargetScan 13 using the inversely related DE mRNAs as a filter to improve prediction efficiency.
14-17 TargetScan alone predicted 3452±240 mRNA targets/DE miRNA, reduced to 42±6 mRNA targets/DE miRNA when conserving only inversely related DE mRNAs in the TargetScan result (Table S5 ). Heat maps were generated using the differentially expressed (DE) miRNAs (A) and mRNAs (B) to present mouse subject grouping by hierarchical clustering analysis. 19 The 7-day Ang II molecular network showed that downregulation of miR-145a-3p may contribute to increased expression of genes involved in ECM and cell proliferation by direct miRNA-mRNA interaction or indirectly through upregulating expression of TF BRCA1 (breast cancer 1, early onset; Figure S2 ). The 14-day Ang II molecular network revealed that all DE miRNAs are implicated in a putative miRNA-TF coregulatory network regulating expression of genes involved in ECM and developmental processes ( Figure 2C ).
miR-431-5p and Its Target Ehf Are Coregulators in Ang II-Induced Vascular Injury
A candidate approach was used to identify miR-431-5p as potential key miRNA regulator and the TF Ehf as an important coregulatory target in 14-day Ang II-induced vascular injury ( Figure 1B ). Seventeen out of 23 upregulated miRNAs in the 14-day Ang II mice are located in the miRNA cluster of the delta-like homolog 1-type III iodothyronine deiodinase (Dlk1-Dio3) region on chromosome 12qF1 ( Figure S3 ; Table S5 ), which is conserved in humans and localizes on chromosome 14q32. 20 Potential miRNA regulators were identified by correlation between BP and expression levels of 9 out of 17 upregulated Dlk1-Dio3 miRNAs ( Figure 3A) , which included the top 6 most significant 14-day Ang II-induced DE miRNAs (Table  S5) . miR-431-5p was selected as a potential key regulator because (1) it was ranked the most significant DE miRNA; (2) the number of predicted DE targets was ranked the first among the 9 BP-correlated miRNAs; (3) its sequence is 100% conserved in human ( Figure 4A) ; and (4) it has been shown to be upregulated in human atherosclerotic plaques. 21 Among the 32 miR-431-5p targets, 2 TFs, namely GATA binding protein 4 (Gata4) and Ehf, were identified (Table  S12) . EHF was selected as a potential coregulator as the mRNA expression of Ehf but not Gata4 correlated with BP ( Figure 3B ), and because EHF was predicted to regulate 43 times more genes than GATA4 ( Figure 2B ; Table S11 ). Seven of the 9 BP-correlated miRNAs including miR-431-5p (Table  S5 ) are predicted to be regulated by EHF. Moreover, the miR-431-5p binding site on the Ehf 3′ UTR is highly conserved in humans ( Figure 4A) . miR-431-5p, miR-382-5p, and Col1a1 were selected as potential EHF targets for the following reasons. miR-431-5p is the candidate key regulator. miR-382-5p is one of the 7 BP-correlated miRNAs predicted to be regulated by EHF, was ranked the second most significant DE miRNA ( Figure 3B ; Table S5 ), and is 100% conserved in humans ( Figure 4B ).
Furthermore, miR-382-5p was shown to play a role in atherosclerosis 22 and renal fibrosis. [23] [24] [25] It has been previously demonstrated that the gene COL1A1 is repressed by EHF in human prostate epithelial cells, 26 and in addition, collagen deposition participates in vascular remodeling in hypertension. 27 RT-qPCR validated miR-431-5p and Col1a1 upregulation and Ehf downregulation observed in RNA sequencing ( Figure 4C ). Increases in miR-382-5p were also observed but without reaching statistical significance.
miR-431-5p Targets EHF, Which Causes, miR-431-5p, miR-382-5p, and COL1A1 Upregulation
The existence of a miR-431-5p-EHF coregulatory network modulating miR-431-5p, miR-382-5p, and Col1a1 was demonstrated by gain-and loss-of-function experiments in vascular cells (Figure 1C) . RT-qPCR showed that miR-431-5p was expressed ≈5× more in mouse MA SMCs compared with lung endothelial cells and fibroblasts ( Figure 4D ). In human cells, miR-431-5p was expressed to a similar level in HASMCs and aortic fibroblasts, and ≈3× lower in aortic endothelial cells. Considering that the mouse miR-431-5p sequence and miR-431-5p binding site on Ehf 3′ UTR are conserved in humans ( Figure 4A ) and that miR-431-5p is highly expressed in mouse and human VSMCs ( Figure 4D ), HASMCs were used to validate EHF as a miR-431-5p target. Transfection of miR-431-5p mimics decreased EHF mRNA levels by 87% ( Figure 5A ), whereas transfection of miR-431-5p inhibitors increased EHF mRNA levels 1.5-fold. We confirmed that miR-431-5p targets EHF in the canonical miRNA-targeting machinery by showing that cotransfection of miR-431-5p mimics decreased luciferase activity of a reporter vector containing the conserved wild-type but not the mutated human EHF 3′ UTR miR-431-5p binding site ( Figure 5B ).
Given that miR-431-5p mimic and inhibitor transfection directly regulated EHF expression, miR-382-5p and COL1A1 could be indirectly regulated as well. miR-431-5p mimic transfection increased miR-382-5p and COL1A1 1.7-fold ( Figure 5C ). However, miR-431-5p knockdown had little or no effect. miR-431-5p inhibitor transfection did not affect miR-382-5p levels and reduced COL1A1 mRNA levels by 11%. EHF knockdown by small interfering RNA transfection reduced EHF mRNA levels (60%) and increased miR-431-5p (1.3-fold), miR-382-5p (1.4-fold), and COL1A1 (1.2-fold) mRNA levels ( Figure 5D ).
In Vivo miR-431-5p Knockdown Protected Against Ang II-Induced Hypertension and Vascular Damage
We tested whether in vivo miR-431-5p knockdown protects against 14-day Ang II-induced BP elevation and vascular injury ( Figure 1D ). Intravenous injections of miR-431-5p inhibitors decreased miR-431-5p levels in MAs by 89% compared with control ( Figure 6A ). In agreement with in vitro loss-of-function results, in vivo miR-431-5p knockdown led to 2.2-fold increase in Ehf, 42% decrease in Col1a1, and 65% decrease in miR-382-5p in MAs.
Ang II-induced BP elevation was transiently reduced after each miR-431-5p inhibitor injection ( Figure 6B ; Figure S4A and S4B). After control inhibitor injection on day 7, there was a 1-day transient decrease in BP. MA miR-431-5p knockdown improved MA vasorelaxation responses to acetylcholine by 30% ( Figure 6C ). In addition, MA miR-431-5p knockdown reduced MA media/lumen by 13% and diminished MA stiffness ( Figure 6D ). Furthermore, miR-431-5p inhibitor injection caused a ≈60% decrease in reactive oxygen species production in the MA wall and perivascular adipose tissue ( Figure 6E ) and a 31% reduction in adventitial collagen fraction ( Figure S5) .
Renal miR-431-5p and Ehf mRNA expression levels were unaffected by miR-431-5p inhibitor injection in 14-day Ang II-infused mice ( Figure S6 ). miR-431-5p inhibitor injection did not reduce cardiac hypertrophy or kidney weight loss in 14-day Ang II-infused mice (Table S13) . A small amount of myocardial and renal tubular interstitial collagen content was observed in 14-day Ang II-infused mice injected with control miRNA-inhibitors, which tended to be lower in mice injected with miR-431-5p inhibitors ( Figure S7) .
Discussion
The present study demonstrated for the first time a miRNA-TF coregulatory network and identified miR-431-5p encoded in the conserved Dlk1-Dio3 miRNA cluster and expressed in VSMCs, as a regulator in Ang II-induced vascular injury. Gain-and loss-of-function experiments in human VSMCs demonstrated that miR-431-5p targets the TF EHF, and EHF regulates expression of COL1A1, miR-431-5p, and another Dlk1-Dio3 miRNA, miR-382-5p. miR-431-5p knockdown protected against Ang II-induced BP elevation and vascular injury in vivo, which suggests its potential value as therapeutic target in hypertension.
miRNAs associated with vascular injury in hypertension have been identified using a candidate approach. miR-130a was increased in aorta and MAs of spontaneously hypertensive rats compared with normotensive Wistar-Kyoto rats and mediated VSMC proliferation by targeting the TF growth arrest-specific homeobox (Gax). 28 miR-34b was upregulated in aortic SMCs isolated from spontaneously hypertensive rat compared with Wistar-Kyoto rats and decreased VSMC viability by downregulating cyclin-dependent kinase 6 (CDK6) in human VSMCs. 29 Two studies in hypertension used an unbiased genome-wide approach by miRNA microarray profiling. A few upregulated miRNAs were found in aorta of rats infused with Ang II for 10 days, 10 and miR-487b, encoded in the conserved Dlk1-Dio3 miRNA cluster, was reported to target insulin receptor substrate 1 (IRS-1) in adventitial fibroblasts. The second study identified 3 DE miRNAs in small MAs from a spontaneously hypertensive rat at a prehypertensive stage and in established hypertension. 11 However, these studies did not demonstrate causal relationships and underlying mechanisms. In the present study, miRNAs and mRNAs were profiled in MAs at a developing and a developed stage of vascular injury. Whereas a 7-day Ang II infusion caused only MA stiffening, 14 days of Ang II infusion resulted in MA endothelial dysfunction and vascular remodeling in addition to stiffening, together with differential expression of 35× more miRNAs and 5× more mRNAs compared with the 7-day group. The 7-day Ang II-induced DE mRNAs are involved in ECM and cell division, whereas the 14-day Ang II-induced DE mRNAs are involved additionally in developmental processes, cell motility, growth factor signaling, inflammation, etc. We propose that differences in vascular function and mechanics between the 7-and 14-day Ang II-infused mice could be attributed to differences in changes in mRNA expression.
Only miR-145a-3p was found to be DE in MA at a developing stage of vascular injury. miR-145a (formerly known as miR-145) and miR-143 that are coexpressed from a single primary transcript, were shown to play an essential role in VSMCs in the acquisition of a contractile phenotype. 8, 9 miR-145 knockout and miR-143/145 double knockout led to a shift of VSMCs to a synthetic phenotype, which is observed in vascular injury. However, because miR-145a-3p downregulation did not persist at a developed stage of vascular injury, it is unlikely that miR-145a-3p plays an important role in vascular injury in hypertension.
A majority (17 out of 23) of 14-day Ang II upregulated miRNAs were contained within the conserved miRNA cluster of the Dlk1-Dio3 region, which has been involved in aortic adventitial fibroblast survival in hypertension, atherosclerosis, and neovascularization. 14, 28, 29 Furthermore, there was an association between BP and 9 of these miRNAs. Focusing on these 9 miRNAs and associated TFs together with additional candidate selection criteria enabled identifying miR-431-5p and a putative target, EHF, as potential coregulators, and COL1A1, miR-382-5p, and miR-431-5p as EHF targets. DNA hypomethylation of promoters in the DLK1-DIO3 region has been associated with upregulation of 6 DLK1-DIO3 miRNAs including miR-431-5p in human atherosclerosis. 21 miR-431-5p may be upregulated in our study by a similar mechanism. Ang II infusion causes hypomethylation of CpG dinucleotides in the promoters of Cyp11b2 in the adrenal gland 30 and Nkcc1 in aorta. 31 miR-431-5p also plays a role in maintaining the myogenic ability of skeletal muscle, 32 or tumor suppressor 35 in hepatocellular carcinoma, promotes neuronal neurite outgrowth or prevents synapse loss in cerebral ischemia-reperfusion injury and Alzheimer disease 36, 37 and decreases neuronal neurite outgrowth in spinal muscular atrophy and cochlear hearing loss. 38, 39 EHF is a tumor suppressor in prostate and esophageal cancer. 26, 40 It represses transcription of genes involved in epithelial-to-mesenchymal transition and cell stemness in human prostate epithelial cells including COL1A1. 26 miR-382-5p may play a role in atherosclerosis, 22 and renal fibrosis, [23] [24] [25] participates in hematopoietic stem cell differentiation 41 and liver regeneration, 42 is a prostate oncogene, 43 and is a tumor suppressor in metastasis of hepatocellular carcinoma. 44 However, neither miR-431-5p, EHF nor miR-382-5p have been implicated to date in hypertension or vascular injury. None of the miRNA-431-5p and miR-328-5p targets reported in above cited studies were relevant for the current study as they were not expressed or their expression was unchanged or increased in 14-day Ang II mice.
A translational approach was used to validate the candidate miR-TF coregulatory network and potential therapeutic target value of miR-431-5p in hypertension. In human VSMCs using gain-and loss-of-function experiments miR-431-5p directly targeted EHF in the canonical miRNA-targeting machinery, leading to upregulation of COL1A1, miR-431-5p, and miR-382-5p through EHF downregulation. We used human VSMCs to study this miR-TF network because the mouse miR-431-5p sequence and Ehf 3′ UTR miR-431-5p binding site are highly conserved in human. It was also particularly relevant to demonstrate the existence of the miR-431-5p-EHF coregulatory network in human VSMCs. We then showed this miR-TF coregulatory network in MAs of Ang II-infused mice using injection of miR-431-5p inhibitors, and that in vivo miR-431-5p knockdown delayed BP elevation and reduced small MA endothelial function, remodeling, stiffening, oxidative stress, and fibrosis caused by Ang II.
The beneficial effects of anti-miR-431-5p injection could be because of miR-431-5p knockdown in MAs and other tissues important for BP regulation and vascular injury such as the kidney and the immune system. 45, 46 Anti-miR-431-5p injection had limited tissue knockdown capacity. Although efficient on MAs, miR-431-5p expression was unaffected by anti-miR-431-5p injection in the kidney. It is possible that antimiR-431-5p injection caused miR-431-5p knockdown in small arteries of the kidney and other organs. Beyond MA, anti-miR-431-5p injection tended to decrease myocardial and renal tubular interstitial collagen content. The immune system plays a Figure 5 . miR-431-5p targets ETS homologous factor (EHF), which causes, miR-431-5p, miR-382-5p, and COL1A1 upregulation in human aortic vascular smooth muscle cells (HASMCs). A, EHF mRNA expression levels were determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in HASMCs transfected for 24 h with control (Ctrl) or miR-431-5p microRNA (miR) mimics or inhibitors. B, Luciferase activity was measured in HASMCs cotransfected for 48 h with pmirGLO-EHF reporter vectors containing the conserved wild-type or mutated human EHF 3′ untranslated region (UTR) miR-431-5p binding site and Ctrl or miR-431-5p mimics. C, Expression of miR-382-5p and COL1A1 mRNA was determined by RT-qPCR after transfection of Ctrl miR or miR-431-5p mimics or inhibitors. D, Expression of EHF mRNA, miR-431-5p, miR-382-5p, and COL1A1 mRNA was determined by RT-qPCR in HASMCs 24 h after transfection of Ctrl or EHF small interfering RNAs (siRNAs). Expression levels of ribosomal protein S16 (RPS16) and U6 small nuclear RNA (snRNA) were used to normalize the expression of mRNA and miR, respectively. Data are presented as means±SEM, n=6-9. Data were analyzed using paired t test. *P<0.05 vs Ctrl.
key role in Ang II-induced hypertension and vascular injury, 47 and in this study, we predicted that miR-431-5p could target DE proinflammatory genes. The effects of miR-431-5p inhibitor injection on BP were transient. It could be necessary to develop a more efficient miR-431-5p knockdown approach to sustainably reduce Ang II-induced hypertension. Because nitric oxide is the main mediator of the vasodilatory responses to acetylcholine, the beneficial effects MA miR-431-5p knockdown in blunting Ang II-induced endothelial dysfunction could be mediated at least in part by decreases in oxidative stress. Reactive oxygen species play a central role mediating endothelial dysfunction in hypertension by affecting nitric oxide bioavailability. 48 It is unknown how miR-431-5p knockdown decreased oxidative stress in MAs, but because miR-431-5p is at the origin of a large molecular network, the antioxidant effect of miR-431-5p knockdown could be mediated by another miR-431-5p, EHF, or miR-382-5p target not investigated here. The decrease in Col1a1 mRNA and adventitia collagen fraction could have contributed to reduce MA stiffness. Finally, the delay in BP elevation and decrease in oxidative stress could have contributed to reduce vascular remodeling. 27 Lack of effect of the anti-miR-431-5p injection on Ang II-induced cardiac hypertrophy and renal weight loss could be because of insufficient BP lowering or limited tissue knockdown capacity. , C) , media/lumen, and vascular stiffness (D) of small mesenteric arteries using pressurized myography and reactive oxygen species generation by dihydroethidium (DHE) staining (E) in mesenteric artery media adventitia and perivascular adipose tissue (PVAT) were determined in another set of mice treated as above with Ang II and with Ctrl or miR-431-5p miR-inhibitors. Gray arrows in B indicate days of miR-431-5p inhibitor injection. Representative images of DHE staining are shown in E. Red and green fluorescence represent DHE fluorescence and elastin autofluorescence, respectively. Data are presented as means±SEM, n=6-8 in A and 6-7 in B-E. D, the strain values at 140 mm Hg (the last points) were used for analysis. Data were analyzed using t test in A, D, and E and using 2-way repeated measures ANOVA followed by a Bonferroni post hoc test in B and C. *P<0.05 vs Ctrl.
Limitations
Dihydroethidium staining was used to determine reactive oxygen species generation in the vascular wall and perivascular adipose tissue. It is not specific for superoxide production but is a good reporter of reactive oxygen species generation and the only method to localize its cellular origin. We focussed on a miR-431-5p-EHF coregulatory network. However, other miRNAs identified using our systems biology approach have not been investigated as potential therapeutic targets. Nevertheless, by targeting miR-431-5p, we could have indirectly targeted 7 other BP-correlated miRNAs predicted to be EHF targets ( Figure S8 ).
Perspectives
We demonstrate a miRNA-TF coregulatory network and identified miR-431-5p, previously shown to be implicated in human atherosclerosis, as a key regulator in Ang II-induced vascular injury. miR-431-5p knockdown protected against Ang II-induced BP elevation, endothelial dysfunction, and vascular remodeling, stiffening, oxidative stress and fibrosis, suggesting its potential value as a novel therapeutic approach for hypertension and vascular damage.
